Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

1. CAO M, LEITE BN, FERREIRO T, CALVO M, FERNANDEZ C, ALONSO A, et al., Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018; 48: p. 225–233.10.1159/00049286530205388Search in Google Scholar

2. NORIS M and REMUZZI G, Atypical hemolytic–uremic syndrome. N Engl J Med 2009; 361: p. 1676–1687.10.1056/NEJMra090281419846853Search in Google Scholar

3. CAMPISTOL JM, ARIAS M, ARICETA G, BLASCO M, ESPINOSA L, ESPINOSA M, et al., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015; 35: p. 421–447.10.1016/j.nefroe.2015.11.006Search in Google Scholar

4. KATO H, MIYAKAWA Y, HIDAKA Y, INOUE N, ITO S, KAGAMI S, et al., Safety and effectiveness of Eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019; 23: p. 65–75.10.1007/s10157-018-1609-8634438829959568Search in Google Scholar

5. RAINA R, GREWAL MK, RADHAKRISHNAN Y, TATINENI V, DECOY M, BURKE LL, et al., Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019; 12: p. 183.10.2147/IJNRD.S215370673251131564951Search in Google Scholar

6. KRISHNAPPA V, GUPTA M, ELRIFAI M, MOFTAKHAR B, ENSLEY MJ, VACHHARAJANI TJ, et al., Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial 2018; 22: p. 178–188.10.1111/1744-9987.1264129250893Search in Google Scholar

7. LEE H, KANG E, KANG HG, KIM YH, KIM JS, KIM H-J, et al., Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020; 35: p. 25–40.10.3904/kjim.2019.388696004131935318Search in Google Scholar

8. KHWAJA A, KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120: p. c179–c184.10.1159/00033978922890468Search in Google Scholar

9. CAMPISTOL JM, ARIAS M, ARICETA G, BLASCO M, ESPINOSA M, GRINYÓ JM, et al., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia.2015;35(5):421–44710.1016/j.nefroe.2015.11.006Search in Google Scholar

10. FREMEAUX-BACCHI V, FAKHOURI F, GARNIER A, BIENAIMÉ F, DRAGON-DUREY M-A, NGO S, et al., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8: p. 554–562.10.2215/CJN.04760512361394823307876Search in Google Scholar

11. NORIS M, CAPRIOLI J, BRESIN E, MOSSALI C, PIANETTI G, GAMBA S, et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5: p. 1844–1859.10.2215/CJN.02210310297438620595690Search in Google Scholar

12. JOKIRANTA TS, HUS and atypical HUS. Blood, T 2017; 129: p. 2847–2856.10.1182/blood-2016-11-709865544556728416508Search in Google Scholar

13. LEGENDRE CM, LICHT C, MUUS P, GREENBAUM L, BABU S, BEDROSIAN C, et al., Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013; 368: p. 2169–2181.10.1056/NEJMoa120898123738544Search in Google Scholar

14. GOODSHIP TH, COOK HT, FAKHOURI F, FERVENZA FC, FRÉMEAUX-BACCHI V, KAVANAGH D, et al., Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91: p. 539–551.Search in Google Scholar

15. OSBORNE AJ, BRENO M, BORSA NG, BU F, FRÉMEAUX-BACCHI V, GALE DP, et al., Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018; 200: p. 2464–2478.10.4049/jimmunol.1701695632484029500241Search in Google Scholar

16. CAVERO T, RABASCO C, LÓPEZ A, ROMÁN E, ÁVILA A, SEVILLANO Á, et al., Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017; 32: p. 466–474.10.1093/ndt/gfw453541098928339660Search in Google Scholar

17. MERRILL SA, BRITTINGHAM ZD, YUAN X, MOLITERNO AR, SPERATI CJ, and BRODSKY RA, Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 2017; 130: p. 368–372.10.1182/blood-2017-02-770214552047128461395Search in Google Scholar

18. FAKHOURI F, FILA M, PROVÔT F, DELMAS Y, BARBET C, CHÂTELET V, et al., Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017; 12: p. 50–59.10.2215/CJN.06440616522066327799617Search in Google Scholar

19. ARDISSINO G, POSSENTI I, TEL F, TESTA S, SALARDI S, and LADISA V, Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015; 66: p. 172–173.10.1053/j.ajkd.2015.04.01026111906Search in Google Scholar

20. OLSON SR, LU E, SULPIZIO E, SHATZEL JJ, RUEDA JF, and DELOUGHERY TG, When to stop Eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018; 48: p. 96–107.10.1159/00049203330110670Search in Google Scholar

21. FREMEAUX-BACCHI V, MOULTON EA, KAVANAGH D, DRAGON-DUREY M-A, BLOUIN J, CAUDY A, et al., Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006; 17: p. 2017–2025.10.1681/ASN.200510105116762990Search in Google Scholar

22. WIJNSMA KL, DUINEVELD C, VOLOKHINA EB, VAN DEN HEUVEL LP, VAN DE KAR NC, and WETZELS JF, Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018; 33: p. 635–645.10.1093/ndt/gfx19629106598Search in Google Scholar